Tenax Therapeutics (TENX) Cash from Investing Activities (2010 - 2023)
Tenax Therapeutics (TENX) posted quarterly Cash from Investing Activities of $157.0 for Q4 2023, down 96.08% year-over-year from $4000.0 in Q4 2022, and down 90.2% on a QoQ basis from $1602.0 in Q2 2023.
Tenax Therapeutics (TENX) Cash from Investing Activities (2010 - 2023) Analysis & Trends
Tenax Therapeutics has reported Cash from Investing Activities for 14 years, with the latest figure at $157.0 in Q4 2023.
- Cash from Investing Activities for Q4 2023 came in at $157.0, down 96.08% year-over-year; the trailing twelve-month figure through Sep 2024 was $157.0 (down 97.71% YoY), and the FY2023 annual result was $3000.0, up 229.14% from the prior year.
- Cash from Investing Activities fell to $157.0 in Q4 2023, from $1602.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $511538.0 in Q3 2021 and troughed at -$36964.0 in Q1 2021.
- A 5-year average of $27749.6 and a median of $157.0 in 2023 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 18902.15% in 2021 against a maximum downside of 483.95% in 2021.
- A 5-year view of Cash from Investing Activities shows it stood at -$16747.0 in 2019, then surged by 120.94% to $3506.0 in 2020, then plunged by 148.43% to -$1698.0 in 2021, then jumped by 335.57% to $4000.0 in 2022, then tumbled by 96.08% to $157.0 in 2023.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $157.0 in Q4 2023, $1602.0 in Q2 2023, and $1241.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 157.00 |
| Dec 31, 2023 | 157.00 |
| Jun 30, 2023 | 1,602.00 |
| Jun 30, 2023 | 1,602.00 |
| Mar 31, 2023 | 1,241.00 |
| Mar 31, 2023 | 1,241.00 |
| Dec 31, 2022 | 4,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Mar 31, 2022 | -6,323.00 |
| Mar 31, 2022 | -6,323.00 |
| Dec 31, 2021 | -1,698.00 |
| Dec 31, 2021 | -1,698.00 |
| Sep 30, 2021 | 511,538.00 |
| Sep 30, 2021 | 511,538.00 |
| Jun 30, 2021 | -20,267.00 |
| Jun 30, 2021 | -20,267.00 |
| Mar 31, 2021 | -36,964.00 |
| Mar 31, 2021 | -36,964.00 |
| Dec 31, 2020 | 3,506.00 |
| Dec 31, 2020 | 3,506.00 |